Biogen Inc. (BIIB) has been the center of many notable market movements and analyst speculations. The company's Alzheimer's drug
Leqembi received approval from the European Union, marking a significant milestone for the company and the patients the drug benefits. Furthermore, Biogen also received acceptance for its Leqembi application in
China, expanding their market reach. Several analysts have shifted their targets for Biogen, with Citigroup and Truist Securities raising theirs to $180 and $190, respectively. The company also endured a one-time $471M loss, causing some doubts over its profit narrative. However, the increased confidence in Leqembi and the MS pipeline might change this outlook. Unexpectedly, the
HSBC downgraded Biogen despite its pipeline progress. The company's Q3 earnings managed to top estimates and the company continues to expand with recent buys such as
Alcyone. There is renewed interest in Biogen's Neurology pipeline and the consideration of Biogen's valuation represents an ongoing discussion among investors and analysts.
Biogen BIIB News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 10 Jan 2026 21:48:17 GMT -
Rating 3
- Innovation 7
- Information 5
- Rumor -2
